Dr. Moritz Hillgenberg, the founder of Hillgenberg Pharma Biotech Consulting, has has a wide range of experience in the life sciences gained in over 15 years working in academic research, biotechnology R&D, pharmaceutical drug development, and consulting. He has a dual qualification in life sciences and economics holding a PhD in Molecular Biology from Humboldt-University Berlin, and an MBA from the Institute of Management Berlin, and combines on-hand experience in research and drug development with sound understanding of healthcare markets.
Since 2007, Dr. Hillgenberg provides independent consultancy services, delivering in-depth understanding of the commercial potential of products as a basis for strategic decision-making. Since 2008, he is also a core team member of groupH, a UK-based international healthcare consulting firm (www.grouph.co.uk ). He also recently started “clinvaluate”, a multidisciplinary combined clinical-commercial evaluation service offered together with Schott Consulting in Clinical Research (www.clinvaluate.com). Over the last 5 years, a large variety of projects have been executed for small or medium Biotech and Medtech companies as well as global Pharma companies in EU, US, and Asia.
Before entering the consulting field, he served as Chief Operations Officer at OSSOGEN Biopharm GmbH and BiRDS Pharma GmbH (both Berolina Drug Development Group), where he headed the development activities for the several drug development projects (including Biologics, NCEs, and Generics). Before that, he held positions as Scientific Director of Custos Biotechnologie GmbH and as project leader in the gene therapy program at HepaVec AG and Develogen AG. He started is career as academic researcher at Max Delbrück Center for Molecular Medicine (MDC) and the German Cancer Research Center (DKFZ), and is author of 10 research papers and 5 international patent families.
Dr. Hillgenberg is co-founder of Conelis e.V. and served as first vice chairman of its board.
